Elevated Rho-kinase activity as a marker indicating atherosclerosis and inflammation burden in polyvascular disease patients with concomitant coronary and peripheral arterial disease

Clinical Cardiology

Volumn 36, Issue 6, 2013, Pages 347-351

  Dong, Ming ^a   Jiang, Xin ^b,c   Liao, James K ^e   Yan, Bryan P ^d  

^a Shenzhen University School of Medicine   (China)

^b JINAN UNIVERSITY   (China)

^c UNIVERSITY OF CHICAGO   (United States)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

MYOSIN; RHO KINASE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ANKLE BRACHIAL INDEX; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR INFLAMMATION; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DISEASE MARKER; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VASCULAR DISEASE; PREDICTIVE VALUE; PROGNOSIS; PROTEIN PHOSPHORYLATION; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; ANKLE BRACHIAL INDEX; AREA UNDER CURVE; BIOLOGICAL MARKERS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FEMALE; HUMANS; INFLAMMATION; LEUKOCYTES; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PERIPHERAL VASCULAR DISEASES; PHOSPHORYLATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RHO-ASSOCIATED KINASES; ROC CURVE; SEVERITY OF ILLNESS INDEX; UP-REGULATION;

EID: 84879122131     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22118     Document Type: Article

References (23)

1. Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007; 297: 1197-1206.
2. Moussa ID, Jaff MR, Mehran R, et al. Prevalence and prediction of previously unrecognized peripheral arterial disease in patients with coronary artery disease: the Peripheral Arterial Disease in Interventional Patients Study. Catheter Cardiovasc Interv. 2009; 73: 719-724.
3. Wilson WR, Fitridge RA, Weekes AJ, et al. Quality of life of patients with peripheral arterial disease and chronic stable angina. Angiology. 2012; 63: 223-228.
4. Dong M, Yan BP, Liao JK, et al. Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases. Drug Discov Today. 2010; 15: 622-629.
5. Bussemaker E, Pistrosch F, Forster S, et al. Rho kinase contributes to basal vascular tone in humans: role of endothelium-derived nitric oxide. Am J Physiol Heart Circ Physiol. 2007; 293: H541-H547.
6. Liu PY, Liao JK,. A method for measuring Rho kinase activity in tissues and cells. Methods Enzymol. 2008; 439: 181-189.
7. Noma K, Goto C, Nishioka K, et al. Smoking, endothelial function, and Rho-kinase in humans. Arterioscler Thromb Vasc Biol. 2005; 25: 2630-2635.
8. Noma K, Goto C, Nishioka K, et al. Roles of rho-associated kinase and oxidative stress in the pathogenesis of aortic stiffness. J Am Coll Cardiol. 2007; 49: 698-705.
9. Feske SK, Sorond FA, Henderson GV, et al. Increased leukocyte ROCK activity in patients after acute ischemic stroke. Brain Res. 2009; 1257: 89-93.
10. Montaner S, Perona R, Saniger L, et al. Multiple signalling pathways lead to the activation of the nuclear factor kappaB by the Rho family of GTPases. J Biol Chem. 1998; 273: 12779-12785.
11. Higashi M, Shimokawa H, Hattori T, et al. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ Res. 2003; 93: 767-775.
12. Radeff JM, Nagy Z, Stern PH,. Rho and Rho kinase are involved in parathyroid hormone-stimulated protein kinase C alpha translocation and IL-6 promoter activity in osteoblastic cells. J Bone Miner Res. 2004; 19: 1882-1891.
13. Funakoshi Y, Ichiki T, Shimokawa H, et al. Rho-kinase mediates angiotensin II-induced monocyte chemoattractant protein-1 expression in rat vascular smooth muscle cells. Hypertension. 2001; 38: 100-104.
14. Hattori T, Shimokawa H, Higashi M, et al. Long-term treatment with a specific Rho-kinase inhibitor suppresses cardiac allograft vasculopathy in mice. Circ Res. 2004; 94: 46-52.
15. Morishige K, Shimokawa H, Eto Y, et al. Adenovirus-mediated transfer of dominant-negative rho-kinase induces a regression of coronary arteriosclerosis in pigs in vivo. Arterioscler Thromb Vasc Biol. 2001; 21: 548-554.
16. Hernandez-Perera O, Perez-Sala D, Soria E, et al. Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. Circ Res. 2000; 87: 616-622.
17. Nohria A, Prsic A, Liu PY, et al. Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis. 2009; 205: 517-521.
18. Kikuchi Y, Yasuda S, Aizawa K, et al. Enhanced Rho-kinase activity in circulating neutrophils of patients with vasospastic angina: a possible biomarker for diagnosis and disease activity assessment. J Am Coll Cardiol. 2011; 58: 1231-1237.
19. Hung MJ, Cherng WJ, Hung MY, et al. Increased leukocyte Rho-associated coiled-coil containing protein kinase activity predicts the presence and severity of coronary vasospastic angina. Atherosclerosis. 2012; 221: 521-526.
20. Mota AP, de Castro Santos ME, Lima e Silva FC, et al. Hypercoagulability markers in patients with peripheral arterial disease: association to ankle-brachial index. Angiology. 2009; 60: 529-535.
21. Fung ET, Wilson AM, Zhang F, et al. A biomarker panel for peripheral arterial disease. Vasc Med. 2008; 13: 217-224.
22. Krause KJ, Williams DS, White N,. Baseline distribution and correlation analysis of hsCRP in an insurance applicant population. J Insur Med. 2008; 40: 124-129.
23. Noma K, Rikitake Y, Oyama N, et al. ROCK1 mediates leukocyte recruitment and neointima formation following vascular injury. J Clin Invest. 2008; 118: 1632-1644.